Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

3 1

What is this study about?

This clinical trial is focused on studying a skin condition called Hidradenitis Suppurativa, which is a chronic inflammatory disease that causes painful lumps under the skin. The study is testing a medication called Povorcitinib (also known by its code name INCB054707) to see how effective and safe it is for people with moderate to severe forms of this condition. Participants in the study will receive either the medication or a placebo, which is a substance with no active ingredients, to compare the effects.

The purpose of the study is to evaluate how well Povorcitinib works in reducing the symptoms of Hidradenitis Suppurativa and to monitor any side effects. The study will last for a period of up to 54 weeks, during which participants will take the medication in the form of oral tablets. Throughout the study, participants will have regular check-ups to assess their response to the treatment and any changes in their condition.

Participants will be monitored for improvements in their symptoms, such as a reduction in the number of painful lumps and overall skin condition. The study aims to provide valuable information on the potential benefits of Povorcitinib for individuals suffering from this challenging skin disease.

1 joining the study

Upon joining the study, you will be asked to sign a document called an informed consent form. This form confirms that you understand the study and agree to participate.

You will need to confirm that you are willing and able to follow the study procedures and that you meet the eligibility criteria, such as being 18 years or older and having a diagnosis of moderate to severe hidradenitis suppurativa for at least three months.

2 initial assessment

An initial assessment will be conducted to evaluate your condition. This includes counting the number of abscesses and inflammatory nodules you have.

Your hidradenitis suppurativa lesions must be present in at least two distinct areas of your body, with at least one area being classified as Hurley Stage II or III.

3 medication administration

You will be given **Povorcitinib** oral tablets to take as part of the study. The dosage and frequency will be determined by the study team.

It is important to follow the instructions provided for taking the medication and to avoid using certain other treatments for hidradenitis suppurativa during the study period.

4 regular check-ups

Throughout the study, you will have regular check-ups to monitor your progress. These visits will include assessments of your skin condition and any changes in your symptoms.

The study team will evaluate your response to the medication and any side effects you may experience.

5 evaluation of results

At the end of the study period, your results will be evaluated to determine the effectiveness and safety of **Povorcitinib** for treating hidradenitis suppurativa.

The primary goal is to see if there is a significant improvement in your condition, measured by the Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12.

Who Can Join the Study?

Ability to understand and willingness to sign a written consent form for the study.
Willing and able to follow the study rules and procedures.
Must be at least 18 years old at the time of signing the consent form.
Must have been diagnosed with moderate to severe Hidradenitis Suppurativa (HS) for at least 3 months before the screening visit.
Must have a total of at least 5 abscesses and inflammatory nodules at both the screening and baseline visits.
Must have HS lesions in at least 2 different body areas (such as left and right armpits or groin areas), with at least one area being at Hurley Stage II or III at both the screening and baseline visits. Hurley Stage II and III refer to more advanced stages of HS.
Must have a documented history of not responding well to at least a 3-month course of at least one conventional systemic therapy (such as oral antibiotics or biologic drugs) for HS, or must have shown intolerance or have a reason not to use such treatments.
Must agree NOT to use topical and systemic antibiotics for treating HS during the placebo-controlled period, unless specific criteria are met.
Must agree NOT to use diluted bleach baths or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on areas affected by HS lesions during the placebo-controlled period. Regular soap and water are allowed.
Must agree to use contraception.

Who Cannot Join the Study?

Patients with any other skin conditions that might interfere with the study.
Patients who have had a recent infection that required treatment with antibiotics.
Patients who have a history of cancer, except for certain types of skin cancer that have been treated.
Patients who have a weakened immune system, which means their body has a harder time fighting infections.
Patients who are currently using other medications that might interfere with the study treatment.
Patients who have participated in another clinical trial recently.
Patients who are pregnant or breastfeeding.
Patients who have a history of drug or alcohol abuse.
Patients who have any other medical condition that the study doctors think might make it unsafe for them to participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
IRCCS Humanitas Research Hospital	Rozzano	Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Rome	Italy
Royalderm Agnieszka Nawrocka	Warsaw	Poland
Universitaetsmedizin Goettingen	Goettingen	Germany

Other Sites

Site Name	City	Country
Centre Hospitalier Universitaire Rouen	Rouen	France
Centre Hospitalier Universitaire De Nice	Nice	France
Hospital General Universitario Gregorio Maranon	Madrid	Spain
Dkc Fokus-5 Lzip OOD	Sofia	Bulgaria
Hms GmbH	Merzig	Germany
Mqtmapl Czszts Hhre Euuu	Sofia	Bulgaria
Utqgzrksqtroxjfzfojur Efqgtadl Akd	Erlangen	Germany
Facyitaofz Iutev Cs Gkgluc Oszhfugy Megcxgzt Pvwfxkkzvyo	Milan	Italy
Hjxakopd Ufbxqypfhnzbj Fhtwoczqc Jtqfnhu Daqr	Madrid	Spain
Uhjedrvjullpeouju Pcepvbfkbvt Dxjnp Mcstfy	Ancona	Italy
Axhqmks Ogikguvwhes Urkawuboqcjhl Flsgbojg Ib Dt Nyuaiy	Naples	Italy
Uoaljsnwmtbalpnufgnua Hbzkpmsmec Ady	Heidelberg	Germany
Rtsmlb Mftapfzgpmx	Aarhus	Denmark
Hhvjhzs Pkslx D Arizdv	Antony	France
Umpnpydbwrdbnucykfunl Swnouxelamyftxejbf And	Kiel	Germany
Hyzetevr Uqxzbzodkxydq Dv Lk Pnhmcjwk	Madrid	Spain
Uuyyvfiiwl Drpne Sjfpi Dt Bzwglfk	Brescia	Italy
Hsf Sbqjgw Agiz	Toulon	France
Aruabia Orpjwquwwgdrdwpfsgjgsuddv Pxdrkenqjqp Gv Rnyagvyvqbhr Msnod Dm Ckoyzbi	Catania	Italy
Uqrrrtxterisy Smgxcys Kffwcochb Idysgrretzzw Ccxxjau W Rmyqsergg	Rzeszow	Poland
Pudvmybvmcce dw Cqxqzafcm	Bezannes	France
Lbogukl Snladwqbqplnspr Gcihlcv Dillkbxskilvmds	Lublin	Poland
Aake – Ikgms &vcrjkv Sokf Aea Vkodywnr Dpmopkrc	Sofia	Bulgaria
Cylinf Hprddnbhkor Ubrhkgtrrqrzn Dp Dqlzv	Dijon	France
Ulwzqsdaeixgfepcu Da Pcfw	Pisa	Italy
Phbalalnx Iqxgfslw Mfxmawia Mmxjvatajjcj Svyqa Wpnrzzpcfukr I Aruviutgtszpb	Warsaw	Poland
Mvgktqck Mgkcwid Ajorkhu	Pleven	Bulgaria
Swz Jyqustqhseasqx	Bochum	Germany
Sbuamosjnhzx Kxsfpeyh Dequzu	Dessau-Roßlau	Germany
Cnmmplr Rajkobai Ozdkjvqiwaki Gycu	Berlin	Germany
Hcbpexyc Ekyjafx Hmngkiw	Lyon	France
Uzccuqvxdh Oo Lkfpnqd	Luebeck	Germany
Uivli &kbvvju Pqpmn Diu Sipfgf Kxcuqkydr Ag	Stara Zagora	Bulgaria
Eq Hkscugyi Unkxzdhkvbgtg Dd Giiu Caemjil Dlb Ntpgzl	Las Palmas De Gran Canaria	Spain
Znefcth Ugiacrryfj Hkrgeniw	Koege	Denmark

Trial status

Country	Status	Recruitment Start
Bulgaria	Not recruiting	15.05.2023
Denmark	Not recruiting	15.05.2023
France	Not recruiting	15.05.2023
Germany	Not recruiting	15.05.2023
Italy	Not recruiting	15.05.2023
Poland	Not recruiting	15.05.2023
Spain	Not recruiting	15.05.2023

Trial locations

Investigated Drugs:

4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide

Povorcitinib is a medication being studied for its potential to help people with a skin condition called hidradenitis suppurativa. This condition causes painful lumps under the skin, often in areas like the armpits or groin. Povorcitinib works by targeting specific pathways in the body that are involved in inflammation, which is a key part of this skin condition. By reducing inflammation, the medication aims to decrease the number and severity of these painful lumps, improving the quality of life for those affected. The study is focused on understanding how effective and safe this medication is for people with moderate to severe forms of the condition.

Investigated Diseases:

Hidradenitis

Hidradenitis Suppurativa – Hidradenitis Suppurativa is a chronic skin condition characterized by the formation of painful lumps under the skin, typically in areas where skin rubs together, such as the armpits, groin, and under the breasts. These lumps can become inflamed and may rupture, leading to the formation of abscesses and tunnels under the skin. Over time, the condition can cause scarring and the development of sinus tracts, which are channels that connect the lumps under the skin. The disease often progresses with periods of flare-ups and remission. The severity and frequency of these flare-ups can vary widely among individuals. The condition is thought to be related to inflammation of the hair follicles and is not contagious.

Trial ID:

2022-501753-36-00

Protocol code:

INCB 54707-302

NCT ID:

NCT05620836

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?